Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03556293 · ClinicalTrials.gov registry record · NA
IMPROVE AKI Cluster-Randomized Trial
A NA study, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 10,252
- Enrollment target
NCT03556293 is a NA study that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 10,252 participants.
The verdict
NCT03556293, a NA study, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 10,252 participants
- Enrollment target
Study Summary
When a person has an imaging procedure that uses radio-contrast dye, there is a possibility of damage to that person's kidneys, which could result in being on dialysis or early death. The investigators are testing novel coaching and automated tools to help healthcare teams apply approaches that have been shown to prevent damage to kidneys during a cardiac catheterization procedure. The results of our study will help inform health care leaders on how to implement low-cost preventive strategies through team-based coaching and surveillance reporting for kidney injury and other patient safety priorities to every hospital in the United States.
Interventions
- BEHAVIORAL AKI Prevention Toolkit
- BEHAVIORAL Technical Assistance (TA)
- BEHAVIORAL Virtual Learning Collaborative (VLC)
- BEHAVIORAL Automated Surveillance Reporting (ASR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,252 participants |
| Start Date | 2019-09-01 |
| Est. Completion | 2023-01-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03556293
The ClinicalTrials.gov registry entry for NCT03556293 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10,252 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which AKI Prevention Toolkit is the first listed.
NCT03556293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03556293 about?
NCT03556293 is a clinical study titled "IMPROVE AKI Cluster-Randomized Trial". When a person has an imaging procedure that uses radio-contrast dye, there is a possibility of damage to that person's kidneys, which could result in being on dialysis or early death. The investigators are testing novel coaching and automated tools to help healthcare teams apply approaches that have...
What is the current status of trial NCT03556293?
This trial is currently completed. It is a NA study. The enrollment target is 10,252 participants. The study started on 2019-09-01. Estimated completion is 2023-01-31.
What interventions are being tested in trial NCT03556293?
The interventions under investigation include: AKI Prevention Toolkit (BEHAVIORAL), Technical Assistance (TA) (BEHAVIORAL), Virtual Learning Collaborative (VLC) (BEHAVIORAL), Automated Surveillance Reporting (ASR) (BEHAVIORAL).
Who is sponsoring clinical trial NCT03556293?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.